학술논문
Deficiencies in the Recognition and Reporting of Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus; A Hungarian Nationwide Analysis.
Document Type
Academic Journal
Author
Ladányi E; Fresenius Medical Care Nephrology Center, Miskolc, Hungary.; Salfer B; AstraZeneca Ltd., Budapest, Hungary.; Balla J; Department of Nephrology, Institute of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.; Kárpáti I; Department of Nephrology, Institute of Internal Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.; Reusz G; First Department of Pediatrics, Semmelweis University, Budapest, Hungary.; Szabó L; AstraZeneca Ltd., Budapest, Hungary.; Andriska P; Healthware Consulting Ltd., Budapest, Hungary.; Németh L; Healthware Consulting Ltd., Budapest, Hungary.; Wittmann I; Second Department of Medicine and Nephrology-Diabetes Center, University of Pécs Medical School, Pécs, Hungary.; Laczy B; Second Department of Medicine and Nephrology-Diabetes Center, University of Pécs Medical School, Pécs, Hungary.
Source
Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101304551 Publication Model: eCollection Cited Medium: Internet ISSN: 1661-8564 (Electronic) Linking ISSN: 16618556 NLM ISO Abbreviation: Int J Public Health Subsets: MEDLINE
Subject
Language
English
Abstract
Objectives: Recognition of chronic kidney disease (CKD) is crucial in type 2 diabetes mellitus (T2DM). We conducted a nationwide epidemiological study to evaluate T2DM-associated CKD in Hungary between 2016 and 2020. Methods: Annual incidence and prevalence rates of registered CKD amongst all pharmacologically treated T2DM patients were analyzed in different age-groups by the central database of the Hungarian Health Insurance Fund Management. Statistical methods included Poisson regression, Bonferroni test, Chi-square test. Results: We found 499,029 T2DM patients and 48,902 CKD patients in 2016, and 586,075 T2DM patients and 38,347 CKD patients in 2020. The majority of all prevalent T2DM and CKD patients were older (aged 60-69 years: 34.1% and 25.8%; ≥70 years: 36.1% and 64.4%, respectively). The annual incidence of T2DM and incidence rates of CKD in T2DM decreased in 2017-2020 ( p < 0.001). The annual prevalence of T2DM increased ( p < 0.01), the prevalence rates of CKD in T2DM were low and decreased from 9.8% to 6.5% in 2016-2020 ( p < 0.001). Conclusion: Incidence and prevalence of T2DM-associated CKD decreased significantly in Hungary in 2016-2020. Lower prevalence rates of CKD may suggest under-recognition and/or under-reporting.
Competing Interests: BS and LS are full time employees of AstraZeneca Hungary Ltd. Authors PA and LN were employed by the company Healthware Consulting Ltd. The remaining authors declare that they do not have any conflicts of interest. The study was delivered with the financial support of AstraZeneca. In this retrospective epidemiological study, no drugs were supplied or funded. The funder had the following involvement with the study: concept, design, and data collection; additionally an AstraZeneca team reviewed this manuscript for scientific accuracy during its development and was allowed to make suggestions.
(Copyright © 2023 Ladányi, Salfer, Balla, Kárpáti, Reusz, Szabó, Andriska, Németh, Wittmann and Laczy.)
Competing Interests: BS and LS are full time employees of AstraZeneca Hungary Ltd. Authors PA and LN were employed by the company Healthware Consulting Ltd. The remaining authors declare that they do not have any conflicts of interest. The study was delivered with the financial support of AstraZeneca. In this retrospective epidemiological study, no drugs were supplied or funded. The funder had the following involvement with the study: concept, design, and data collection; additionally an AstraZeneca team reviewed this manuscript for scientific accuracy during its development and was allowed to make suggestions.
(Copyright © 2023 Ladányi, Salfer, Balla, Kárpáti, Reusz, Szabó, Andriska, Németh, Wittmann and Laczy.)